Gastrointestinal Malignancies Clinical Trials
Category:Adult
Status:Active
Displaying trials 1 - 30 of 46 in total
The purpose of this study is to evaluate the safety and efficacy of ramucirumab in participants with hepatocellular carcinoma (HCC) and elevated baseline alpha-fetoprotein. Participants will be ran...
Diagnosis: Gastrointestinal Malignancies, Liver Cancer
Phase: 3
Protocol Number: 15-287
This is a Phase 3, prospective, multi-center, randomized, double-blind, study evaluating the efficacy and safety of LAN plus BSC versus placebo plus BSC for the treatment of well-differentiated, me...
Diagnosis: Gastrointestinal Malignancies
Phase: 3
Protocol Number: 16-032
The purpose of this study is to compare the efficacy and safety of PEGylated Recombinant Human Hyaluronidase (PEGPH20) combined with nab-paclitaxel plus gemcitabine (PAG treatment), compared with p...
Diagnosis: Gastrointestinal Malignancies, Pancreatic Cancer
Phase: 3
Protocol Number: 16-146
The purpose of this study is to determine whether nivolumab will improve overall survival, disease-free survival, or both compared with placebo.
Diagnosis: Esophageal Cancer, Gastrointestinal Malignancies
Phase: 3
Protocol Number: 16-197
This randomized phase III trial studies how well gemcitabine hydrochloride and cisplatin with or without radiation therapy work in treating patients with localized liver cancer that cannot be remov...
Diagnosis: Liver Cancer, Gastrointestinal Malignancies
Phase: 3
Protocol Number: 15-710
The standard treatment for locally advanced rectal cancer involves chemotherapy and radiation, known as 5FUCMT, (the chemotherapy drugs 5-fluorouracil/capecitabine and radiation therapy) prior to s...
Diagnosis: Colorectal Cancer, Gastrointestinal Malignancies
Phase: 2 / 3
Protocol Number: 12-023
FOLFOX +/- Ziv-Aflibercept for Esophageal and Gastric Cancer
This research study is a Phase II clinical trial to test the safety and effectiveness of the investigational drug Ziv-aflibercept in combination with mFOLFOX6 compared to mFOLFOX6 alone. The drugs ...
Diagnosis: Gastrointestinal Malignancies, Esophageal Cancer, Stomach Cancer
Phase: 2
Protocol Number: 12-401
Sorafenib + mFOLFOX for Hepatocellular Carcinoma
This research study is a Phase II clinical trial. Phase II clinical trials test the effectiveness of an investigational combination of drugs to learn whether the drug combination works in treating ...
Diagnosis: Gastrointestinal Malignancies, Liver Cancer
Phase: 2
Protocol Number: 12-218
Ziv-Aflibercept for Advanced Progressive Carcinoid Tumors
This research study is a Phase II clinical trial, which tests the safety and effectiveness of an investigational drug to learn whether the drug works in treating a specific cancer. "Investigat...
Diagnosis: Gastrointestinal Malignancies, Neuroendocrine/Carcinoid
Phase: 2
Protocol Number: 12-456
The purpose of this research study is to see if cancer will respond better to a combination of irinotecan and cetuximab with or without bevacizumab
Diagnosis: Gastrointestinal Malignancies, Colorectal Cancer
Phase: 2
Protocol Number: 14-574
This research study is evaluating the drug Ramucirumab as a possible treatment for Advanced, Progressive Carcinoid Tumors.
Diagnosis: Neuroendocrine/Carcinoid, Gastrointestinal Malignancies
Phase: 2
Protocol Number: 16-072
The main purpose of this study is to evaluate the efficacy of an alternative dose of ramucirumab in combination with paclitaxel in participants with second-line metastatic or locally advanced, unre...
Diagnosis: Gastrointestinal Malignancies, Esophageal Cancer
Phase: 2
Protocol Number: 15-545
Pembrolizumab in Refractory Metastatic Anal Cancer
This research study is studying a targeted therapy as a possible treatment for advanced anal cancer. The following intervention will be involved in this study: -Pembrolizumab
Diagnosis: Gastrointestinal Malignancies
Phase: 2
Protocol Number: 16-301
Gemcitabine Plus BPM31510 Administered Intravenously in Advanced Pancreatic Cancer Patients
This is a Phase 2 multicenter, open-label, non-randomized study to examine the safety and effectiveness of the combination of BPM31510 administered as a 144-hour continuous intravenous (IV) infusio...
Diagnosis: Pancreatic Cancer, Gastrointestinal Malignancies
Phase: 2
Protocol Number: 17-066
Safety and Efficacy of FGF401 in Patients With Solid Malignancies
Estimate the maximum tolerated dose and/or recommended phase two dose and efficacy of FGF401 on patients with solid malignancies
Diagnosis: Gastrointestinal Malignancies, Stomach Cancer, Liver Cancer, Colorectal Cancer, Pancreatic Cancer, Esophageal Cancer
Phase: 1 / 2
Protocol Number: 14-464
The first part of the study is the Dose Escalation Phase designed to establish the safety of nivolumab at different dose levels for each of the three cohorts (uninfected hepatocellular carcinoma (H...
Diagnosis: Gastrointestinal Malignancies
Phase: 1 / 2
Protocol Number: 15-142
This is a randomized phase II multi-institution prospective open label study in which up to 90 subjects with metastatic, locally advanced unresectable or recurrent pancreatic cancer who previously ...
Diagnosis: Gastrointestinal Malignancies, Pancreatic Cancer
Phase: 1 / 2
Protocol Number: 14-568
Protocol PEN-221-001 is an open-label, multicenter Phase 1/2a study evaluating PEN-221 in patients with SSTR2 expressing advanced gastroenteropancreatic (GEP) or lung or thymus or other neuroendocr...
Diagnosis: Neuroendocrine/Carcinoid, Gastrointestinal Malignancies
Phase: 1 / 2
Protocol Number: 16-450
This main purpose of this clinical study is to learn about the safety and activity of margetuximab and pembrolizumab combination treatment in patients with HER2+ gastric and gastroesophageal juncti...
Diagnosis: Esophageal Cancer, Gastrointestinal Malignancies
Phase: 1 / 2
Protocol Number: 16-258
A Study of DKN-01 in Combination With Paclitaxel
A study to evaluate the safety and tolerability of DKN-01 in combination with weekly paclitaxel in participants with refractory/recurrent esophageal or gastro-esophageal junction cancer.
Diagnosis: Gastrointestinal Malignancies
Phase: 1
Protocol Number: 14-004
Phase 1 Study of MGD007 in Relapsed/Refractory Metastatic Colorectal Carcinoma
The primary goal of this Phase 1 study is to characterize the safety and tolerability of MGD007 and establish the maximum tolerated dose (MTD) of MGD007 administered on either weekly or every three...
Diagnosis: Gastrointestinal Malignancies, Colorectal Cancer
Phase: 1
Protocol Number: 14-524
This study seeks to learn more about the vitamin D receptor and its relationship to colon cancer. The Vitamin D receptor is found in colon cancer cells. When Vitamin D binds to the receptor in the ...
Diagnosis: Gastrointestinal Malignancies, Colorectal Cancer
Phase: 0
Protocol Number: 14-091
This pilot clinical trial studies the best dose of erlotinib hydrochloride and to see how well it works in preventing liver cancer in patients with scarring (cirrhosis) of the liver undergoing surg...
Diagnosis: Gastrointestinal Malignancies
Phase: N/A
Protocol Number: 14-333
Feasibility of the LUM Imaging System for Detection of Gastrointestinal Cancers
The overall goal of this feasibility study is to assess the initial safety and efficacy of LUM015 in ex vivo far-red imaging of colorectal, pancreatic, and esophageal cancers (adenocarcinoma) using...
Diagnosis: Colorectal Cancer, Esophageal Cancer, Gastrointestinal Malignancies, Pancreatic Cancer
Phase: N/A
Protocol Number: 13-415
Pilot Study of a Pharmacy Intervention for Older Adults With Cancer
The purpose of this research study is to address the challenge of medication management for older patients undergoing treatment for cancer. The sponsor of this protocol is the Massachusetts General...
Diagnosis: Breast: Early Stage Disease, Lung Cancer, Gastrointestinal Malignancies
Phase: N/A
Protocol Number: 16-230
The purpose of this study is to evaluate the effect of Cabozantinib (XL184) compared with placebo on overall survival in subjects with advanced hepatocellular carcinoma who have received prior sora...
Diagnosis: Gastrointestinal Malignancies
Phase:
Protocol Number: 15-108
Phase 1 Study of PLX7486 as Single Agent in Patients With Advanced Solid Tumors
The objective of this study is to determine the safety, pharmacokinetics, maximum tolerated dose/recommended Phase 2 dose, and efficacy of PLX7486.
Diagnosis: Gastrointestinal Malignancies
Phase:
Protocol Number: 14-246
A Phase III, Randomised, Double Blind, Placebo Controlled, Multicentre Study of Maintenance Olaparib Monotherapy in Patients with gBRCA Mutated Metastatic Pancreatic Cancer whose Disease Has Not Pr...
Diagnosis: Pancreatic Cancer, Gastrointestinal Malignancies
Phase:
Protocol Number: 15-191
This randomized phase II trial studies how well temozolomide and capecitabine work compared to standard treatment with cisplatin and etoposide in treating patients with neuroendocrine carcinoma of ...
Diagnosis: Gastrointestinal Malignancies, Neuroendocrine/Carcinoid
Phase:
Protocol Number: 16-705
A Phase 1 Study of BLU-554 in Patients With Hepatocellular Carcinoma
This is a Phase 1, open-label, first-in-human (FIH) study designed to evaluate the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD), and preliminary antineoplastic activity of BLU...
Diagnosis: Liver Cancer, Gastrointestinal Malignancies
Phase:
Protocol Number: 16-076
